Skin Diseases in the Immunocompromised.

By: Hall, John CMaterial type: TextTextSeries: eBooks on DemandPublisher: London : Springer, 2014Copyright date: ©2014Description: 1 online resource (199 pages)Content type: text Media type: computer Carrier type: online resourceISBN: 9781447164791Subject(s): Skin -- DiseasesGenre/Form: Electronic books.Additional physical formats: Print version:: Skin Diseases in the ImmunocompromisedDDC classification: 616.5079 LOC classification: R1Online resources: Click here to view this ebook.
Contents:
Intro -- Preface -- Skin Diseases in the Immunocompromised -- Abbreviations -- Contents -- Contributors -- Part I: Disease Specific -- 1: Skin Disorders in Immunocompromised Diabetes Patients -- Introduction -- Skin Manifestations of Diabetes Mellitus Associated with Immunosuppression -- Skin Diseases in Immunocompromised Diabetic Patients -- Bacteria -- Staphylococcus -- Group B Streptococcus -- Clostridium perfringens -- Klebsiella -- Mycobacterium Tuberculosis -- Escherichia Coli -- Morganella -- Mycosis -- Candidiasis -- Zygomycosis -- Cryptococcosis -- Coccidioidomycosis -- Sporotrichosis -- Viral -- Herpes Simplex -- Herpes Zoster -- Algae -- Protothecosis -- Parasites -- Conclusion -- Suggested Reading -- 2: Skin Disorders of AIDS Patients -- Introduction and Historical Perspective -- AIDS-Defining Illnesses -- Infectious Etiologies -- Viral Infections -- Herpes Simplex Virus (HSV) -- Clinical Features -- Diagnosis -- Treatment -- Varicella Zoster Virus (VZV) and Herpes Zoster (HZ) -- Clinical Features -- Diagnosis -- Treatment -- Cytomegalovirus (CMV) -- Clinical Features -- Diagnosis -- Treatment -- Epstein-Barr Virus (EBV) -- Clinical Features -- Diagnosis -- Treatment -- Molluscum Contagiosum -- Clinical Features -- Diagnosis -- Treatment -- Human Papillomavirus (HPV) and Anal Cancer -- Clinical Features -- Diagnosis -- Treatment -- Fungal Infections -- Oral Candidiasis -- Clinical Features -- Diagnosis -- Treatment -- Onychomycosis -- Clinical Features -- Diagnosis -- Treatment -- Cutaneous Manifestations of Systemic Infections -- Cryptococcosis -- Coccidoidomycosis -- Histoplasmosis -- Diagnosis -- Management -- Bacterial Infections -- Syphilis -- Clinical Features -- Diagnosis -- Treatment -- Bacillary Angiomatosis -- Clinical Features -- Diagnosis -- Management -- Staphylococcal Skin Disease -- Clinical Features -- Diagnosis.
Treatment -- Mycobacterial Infection -- Clinical Features -- Diagnosis -- Management -- Parasites and Infestations -- Scabies -- Clinical Features -- Diagnosis -- Treatment -- Neoplastic Lesions -- Kaposi's Sarcoma -- Clinical Features -- Diagnosis -- Therapy -- Cutaneous Lymphomas -- Clinical Features -- Diagnosis -- Treatment and Prognosis -- Squamous Cell Carcinoma and Basal Cell Carcinoma -- Inflammatory Disorders -- Eosinophilic Pustulosis (Ofuji Disease) -- Clinical Features -- Treatment -- Drug Reactions -- NRTI -- NNRTI -- Protease Inhibitors -- Immune Reconstitution Inflammatory Syndrome (IRIS) -- Inflammatory Skin Diseases -- Seborrheic Dermatitis -- Treatment -- Psoriasis -- Treatment -- Pruritic Papular Dermatitis of AIDS -- Clinical Manifestation -- Treatment -- Other Inflammatory Skin Diseases -- Conclusion -- Suggested Reading -- 3: Skin Disorders in Patients with Primary Immunodeficiencies -- Introduction -- Combined Immunodeficiencies -- Severe Combined Immunodeficiency (SCID) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Hyper IgM, Hyper Immunoglobulin M Syndrome -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Well-Defined Syndromes with Immunodeficiency -- Wiskott-Aldrich Syndrome (WAS) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Ataxia-Telangiectasia (AT) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Hyper Immunoglobulin E Syndrome (HIES) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Predominantly Antibody Deficiencies -- Bruton's Agammaglobulinemia (XLA) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Selective Immunoglobulin (IgA) Deficiencies -- Genetics and Pathophysiology.
Clinical Manifestations -- Diagnosis -- Management -- Common Variable Immunodeficiency (CVID) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Diseases of Immune Dysregulation -- Chediak-Higashi Syndrome (CHS) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Congenital Defects of Phagocyte Number, Function, or Both -- Leukocyte Adhesion Deficiency (LAD) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Chronic Granulomatous Disease (CGD) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Defects in Innate Immunity -- Chronic Mucocutaneous Candidiasis (CMC) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Autoinflammatory Disorders -- Muckle-Wells Syndrome (MWS) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Complement Deficiencies -- C2 Deficiencies -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Conclusion -- Suggested Reading -- 4: Cancer Patients and Skin Disease -- Introduction -- Infections -- Candidiasis -- Cellulitis -- Herpes Zoster and Herpes Simplex -- Paraneoplastic Skin Disease -- Inflammatory Paraneoplastic Skin Disease -- Pyoderma Gangrenosum -- Sweet's Syndrome -- Figurate Erythemas -- Paraneoplastic Pemphigus -- Vasculitis -- Erythema Nodosum -- Dermatomyositis -- Glucagonoma Syndrome -- Paraneoplastic Tumors of the Skin -- Pigmentary Changes -- Hypercoagulability Syndromes -- Metabolic Paraneoplastic Skin Disease -- Nonspecific Inflammatory Paraneoplastic Skin Disease -- Conclusion -- Suggested Reading -- Part II: Transplant Patients -- 5: Skin Disease in Solid Organ Transplant Patients -- Introduction -- Tumors -- Infections -- Inflammatory Skin Diseases.
Conclusion -- Suggested Reading -- 6: Graft vs Host Disease and Skin Manifestations -- Introduction -- Classification -- Acute GVHD -- Chronic GVHD -- Management -- Conclusion -- Suggested Reading -- Part III: Drug Related -- 7: Cutaneous Reactions to the Biologics -- Introduction -- Infection -- Bacterial Infection -- Mycobacterial Infection -- Tuberculosis -- Leprosy -- Other Mycobacterial Infections -- Staphylococcal Infection -- Streptococcal Infection -- Less-Common Bacterial Infections -- Viral Infection -- Hepatitis Viruses -- Hepatitis C Virus -- Hepatitis B Virus -- Human Herpes Virus Infections -- Herpes Simplex Viruses (HHV-1 and HHV-2) -- Varicella Zoster Virus (HHV-3) -- Cytomegalovirus (HHV-5) -- Kaposi's Sarcoma-Associated Herpes Virus (HHV-8) -- Other Viral Infections -- Fungal Infection -- Superficial Mycoses -- Subcutaneous and Systemic Mycoses -- Parasitic Infection -- Leishmaniasis -- Malignant Disease -- Cutaneous Lymphoma -- Non-melanoma Skin Cancer -- Melanoma -- Inflammatory and Autoimmune Disorders -- Psoriasis and Psoriasiform Eruptions -- Lichenoid Disorders -- Eczema -- Acne -- Granulomatous Disorders -- Vasculitis -- Lupus Erythematosus -- Alopecia Areata -- Other Adverse Effects -- Conclusion -- Suggested Reading -- 8: Cutaneous Reactions to Chemotherapy -- Introduction -- Mucocutaneous Side Effects of Systemic Chemotherapeutic Agents -- Chemotherapy-Induced Alopecia (CIA) -- Mucositis/Stomatitis -- Extravasation Reactions -- Dyschromia -- Acral Erythema -- Neutrophilic Eccrine Hidradenitis (NEH) -- Onychodystrophy -- Miscellaneous Drug Reactions -- Mucocutaneous Effects of Tyrosine Kinase Inhibitors and Monoclonal Antibodies -- Inhibitors of Epidermal Growth Factor Receptor (EGFR) -- Tyrosine Kinase Inhibitors -- Cutaneous Side Effects of Radiation Therapy When Used in Conjunction with Systemic Chemotherapeutics.
Radiation Recall -- Radiation Enhancement -- Conclusion -- Suggested Reading -- 9: Cutaneous Reactions to Corticosteroids -- Introduction -- Hypersensitivity -- Direct Drug Effects -- Secondary to Immunosuppression -- Bacterial -- Viral -- Fungal -- Cancer -- Conclusion -- Suggested Reading -- 10: Cutaneous Reactions to Tyrosine Kinase Inhibitors -- Introduction -- Understanding Tyrosine Kinase Inhibitors (TKIS) -- The Concept of Targeted Therapy: TKI Targets, Examples, and Indications -- Class 1: Epidermal Growth Factor Receptor and the HER Family Inhibitors -- Description of the Most Significant Dermatological Toxicities Observed -- Management Recommendations for Skin Rash -- Management Recommendations for Rashes on the Scalp -- Management of Dermatological Toxicities Other Than Rash: Nail Changes, Dry Skin, Scaling and Hyperkeratosis, Eyelash Growth -- Relationship Between Toxicity of Rash and Efficacy in Patient Outcome -- Class 2: Vascular Endothelial Growth Factor Receptor/Platelet- Derived Growth Factor Receptor/Mixed Inhibitors -- Description of the Most Significant Dermatological Toxicities Observed -- Hand-Foot Syndrome -- Management Recommendations for Hand-Foot Syndrome -- Skin Rash -- Changes in Skin or Hair Color -- Class 3: Other Inhibitors: BRAF, BCR-ABL, C-KIT, ALK, RET -- BRAF: Class 1 RAF Inhibitors -- Management of BRAF Skin Rash -- RET Inhibitors -- Conclusion -- Suggested Reading -- Part IV: Age Related -- 11: Cutaneous Manifestations of Aging and Immunodeficiency -- Introduction -- Aging Definitions -- Aging and Immunity -- Aging and Inflammation -- Herpes Zoster -- Seborrheic Dermatitis -- Angular Cheilitis -- Candida albicans -- Aging and Skin Cancers -- HIV and Aging -- Seborrheic Keratose -- Conclusion -- Suggested Reading -- Part V: Radiation.
12: UVA and UVB Therapy: Practical Applications and Implications for the Immunosuppressed Patient and Skin Disease.
Summary: As the number of surviving immune suppressed patients continues its rapid increase, the skin manifestations have become increasingly important. AIDS patients and renal, heart, liver, bone marrow and lung transplant patients are surviving longer and are often experiencing skin side effects of immunity suppression. Diabetes is exploding in the USA and offers its own unique brand of immune suppressed skin diseases. Immunosuppressive drugs are being used more frequently and newer biologics and tyrosine kinase drugs have added to new categories of immune suppressed patients. This book aims to clearly elucidate the signs of immune suppressed skin disease to afford early diagnosis and management of this ever-increasing, diverse group of illnesses.
Tags from this library: No tags from this library for this title. Log in to add tags.
Item type Current location Call number URL Status Date due Barcode
Electronic Book UT Tyler Online
Online
R1 (Browse shelf) https://ebookcentral.proquest.com/lib/uttyler/detail.action?docID=1964779 Available EBC1964779

Intro -- Preface -- Skin Diseases in the Immunocompromised -- Abbreviations -- Contents -- Contributors -- Part I: Disease Specific -- 1: Skin Disorders in Immunocompromised Diabetes Patients -- Introduction -- Skin Manifestations of Diabetes Mellitus Associated with Immunosuppression -- Skin Diseases in Immunocompromised Diabetic Patients -- Bacteria -- Staphylococcus -- Group B Streptococcus -- Clostridium perfringens -- Klebsiella -- Mycobacterium Tuberculosis -- Escherichia Coli -- Morganella -- Mycosis -- Candidiasis -- Zygomycosis -- Cryptococcosis -- Coccidioidomycosis -- Sporotrichosis -- Viral -- Herpes Simplex -- Herpes Zoster -- Algae -- Protothecosis -- Parasites -- Conclusion -- Suggested Reading -- 2: Skin Disorders of AIDS Patients -- Introduction and Historical Perspective -- AIDS-Defining Illnesses -- Infectious Etiologies -- Viral Infections -- Herpes Simplex Virus (HSV) -- Clinical Features -- Diagnosis -- Treatment -- Varicella Zoster Virus (VZV) and Herpes Zoster (HZ) -- Clinical Features -- Diagnosis -- Treatment -- Cytomegalovirus (CMV) -- Clinical Features -- Diagnosis -- Treatment -- Epstein-Barr Virus (EBV) -- Clinical Features -- Diagnosis -- Treatment -- Molluscum Contagiosum -- Clinical Features -- Diagnosis -- Treatment -- Human Papillomavirus (HPV) and Anal Cancer -- Clinical Features -- Diagnosis -- Treatment -- Fungal Infections -- Oral Candidiasis -- Clinical Features -- Diagnosis -- Treatment -- Onychomycosis -- Clinical Features -- Diagnosis -- Treatment -- Cutaneous Manifestations of Systemic Infections -- Cryptococcosis -- Coccidoidomycosis -- Histoplasmosis -- Diagnosis -- Management -- Bacterial Infections -- Syphilis -- Clinical Features -- Diagnosis -- Treatment -- Bacillary Angiomatosis -- Clinical Features -- Diagnosis -- Management -- Staphylococcal Skin Disease -- Clinical Features -- Diagnosis.

Treatment -- Mycobacterial Infection -- Clinical Features -- Diagnosis -- Management -- Parasites and Infestations -- Scabies -- Clinical Features -- Diagnosis -- Treatment -- Neoplastic Lesions -- Kaposi's Sarcoma -- Clinical Features -- Diagnosis -- Therapy -- Cutaneous Lymphomas -- Clinical Features -- Diagnosis -- Treatment and Prognosis -- Squamous Cell Carcinoma and Basal Cell Carcinoma -- Inflammatory Disorders -- Eosinophilic Pustulosis (Ofuji Disease) -- Clinical Features -- Treatment -- Drug Reactions -- NRTI -- NNRTI -- Protease Inhibitors -- Immune Reconstitution Inflammatory Syndrome (IRIS) -- Inflammatory Skin Diseases -- Seborrheic Dermatitis -- Treatment -- Psoriasis -- Treatment -- Pruritic Papular Dermatitis of AIDS -- Clinical Manifestation -- Treatment -- Other Inflammatory Skin Diseases -- Conclusion -- Suggested Reading -- 3: Skin Disorders in Patients with Primary Immunodeficiencies -- Introduction -- Combined Immunodeficiencies -- Severe Combined Immunodeficiency (SCID) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Hyper IgM, Hyper Immunoglobulin M Syndrome -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Well-Defined Syndromes with Immunodeficiency -- Wiskott-Aldrich Syndrome (WAS) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Ataxia-Telangiectasia (AT) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Hyper Immunoglobulin E Syndrome (HIES) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Predominantly Antibody Deficiencies -- Bruton's Agammaglobulinemia (XLA) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Selective Immunoglobulin (IgA) Deficiencies -- Genetics and Pathophysiology.

Clinical Manifestations -- Diagnosis -- Management -- Common Variable Immunodeficiency (CVID) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Diseases of Immune Dysregulation -- Chediak-Higashi Syndrome (CHS) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Congenital Defects of Phagocyte Number, Function, or Both -- Leukocyte Adhesion Deficiency (LAD) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Chronic Granulomatous Disease (CGD) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Defects in Innate Immunity -- Chronic Mucocutaneous Candidiasis (CMC) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Autoinflammatory Disorders -- Muckle-Wells Syndrome (MWS) -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Complement Deficiencies -- C2 Deficiencies -- Genetics and Pathophysiology -- Clinical Manifestations -- Diagnosis -- Management -- Conclusion -- Suggested Reading -- 4: Cancer Patients and Skin Disease -- Introduction -- Infections -- Candidiasis -- Cellulitis -- Herpes Zoster and Herpes Simplex -- Paraneoplastic Skin Disease -- Inflammatory Paraneoplastic Skin Disease -- Pyoderma Gangrenosum -- Sweet's Syndrome -- Figurate Erythemas -- Paraneoplastic Pemphigus -- Vasculitis -- Erythema Nodosum -- Dermatomyositis -- Glucagonoma Syndrome -- Paraneoplastic Tumors of the Skin -- Pigmentary Changes -- Hypercoagulability Syndromes -- Metabolic Paraneoplastic Skin Disease -- Nonspecific Inflammatory Paraneoplastic Skin Disease -- Conclusion -- Suggested Reading -- Part II: Transplant Patients -- 5: Skin Disease in Solid Organ Transplant Patients -- Introduction -- Tumors -- Infections -- Inflammatory Skin Diseases.

Conclusion -- Suggested Reading -- 6: Graft vs Host Disease and Skin Manifestations -- Introduction -- Classification -- Acute GVHD -- Chronic GVHD -- Management -- Conclusion -- Suggested Reading -- Part III: Drug Related -- 7: Cutaneous Reactions to the Biologics -- Introduction -- Infection -- Bacterial Infection -- Mycobacterial Infection -- Tuberculosis -- Leprosy -- Other Mycobacterial Infections -- Staphylococcal Infection -- Streptococcal Infection -- Less-Common Bacterial Infections -- Viral Infection -- Hepatitis Viruses -- Hepatitis C Virus -- Hepatitis B Virus -- Human Herpes Virus Infections -- Herpes Simplex Viruses (HHV-1 and HHV-2) -- Varicella Zoster Virus (HHV-3) -- Cytomegalovirus (HHV-5) -- Kaposi's Sarcoma-Associated Herpes Virus (HHV-8) -- Other Viral Infections -- Fungal Infection -- Superficial Mycoses -- Subcutaneous and Systemic Mycoses -- Parasitic Infection -- Leishmaniasis -- Malignant Disease -- Cutaneous Lymphoma -- Non-melanoma Skin Cancer -- Melanoma -- Inflammatory and Autoimmune Disorders -- Psoriasis and Psoriasiform Eruptions -- Lichenoid Disorders -- Eczema -- Acne -- Granulomatous Disorders -- Vasculitis -- Lupus Erythematosus -- Alopecia Areata -- Other Adverse Effects -- Conclusion -- Suggested Reading -- 8: Cutaneous Reactions to Chemotherapy -- Introduction -- Mucocutaneous Side Effects of Systemic Chemotherapeutic Agents -- Chemotherapy-Induced Alopecia (CIA) -- Mucositis/Stomatitis -- Extravasation Reactions -- Dyschromia -- Acral Erythema -- Neutrophilic Eccrine Hidradenitis (NEH) -- Onychodystrophy -- Miscellaneous Drug Reactions -- Mucocutaneous Effects of Tyrosine Kinase Inhibitors and Monoclonal Antibodies -- Inhibitors of Epidermal Growth Factor Receptor (EGFR) -- Tyrosine Kinase Inhibitors -- Cutaneous Side Effects of Radiation Therapy When Used in Conjunction with Systemic Chemotherapeutics.

Radiation Recall -- Radiation Enhancement -- Conclusion -- Suggested Reading -- 9: Cutaneous Reactions to Corticosteroids -- Introduction -- Hypersensitivity -- Direct Drug Effects -- Secondary to Immunosuppression -- Bacterial -- Viral -- Fungal -- Cancer -- Conclusion -- Suggested Reading -- 10: Cutaneous Reactions to Tyrosine Kinase Inhibitors -- Introduction -- Understanding Tyrosine Kinase Inhibitors (TKIS) -- The Concept of Targeted Therapy: TKI Targets, Examples, and Indications -- Class 1: Epidermal Growth Factor Receptor and the HER Family Inhibitors -- Description of the Most Significant Dermatological Toxicities Observed -- Management Recommendations for Skin Rash -- Management Recommendations for Rashes on the Scalp -- Management of Dermatological Toxicities Other Than Rash: Nail Changes, Dry Skin, Scaling and Hyperkeratosis, Eyelash Growth -- Relationship Between Toxicity of Rash and Efficacy in Patient Outcome -- Class 2: Vascular Endothelial Growth Factor Receptor/Platelet- Derived Growth Factor Receptor/Mixed Inhibitors -- Description of the Most Significant Dermatological Toxicities Observed -- Hand-Foot Syndrome -- Management Recommendations for Hand-Foot Syndrome -- Skin Rash -- Changes in Skin or Hair Color -- Class 3: Other Inhibitors: BRAF, BCR-ABL, C-KIT, ALK, RET -- BRAF: Class 1 RAF Inhibitors -- Management of BRAF Skin Rash -- RET Inhibitors -- Conclusion -- Suggested Reading -- Part IV: Age Related -- 11: Cutaneous Manifestations of Aging and Immunodeficiency -- Introduction -- Aging Definitions -- Aging and Immunity -- Aging and Inflammation -- Herpes Zoster -- Seborrheic Dermatitis -- Angular Cheilitis -- Candida albicans -- Aging and Skin Cancers -- HIV and Aging -- Seborrheic Keratose -- Conclusion -- Suggested Reading -- Part V: Radiation.

12: UVA and UVB Therapy: Practical Applications and Implications for the Immunosuppressed Patient and Skin Disease.

As the number of surviving immune suppressed patients continues its rapid increase, the skin manifestations have become increasingly important. AIDS patients and renal, heart, liver, bone marrow and lung transplant patients are surviving longer and are often experiencing skin side effects of immunity suppression. Diabetes is exploding in the USA and offers its own unique brand of immune suppressed skin diseases. Immunosuppressive drugs are being used more frequently and newer biologics and tyrosine kinase drugs have added to new categories of immune suppressed patients. This book aims to clearly elucidate the signs of immune suppressed skin disease to afford early diagnosis and management of this ever-increasing, diverse group of illnesses.

Description based on publisher supplied metadata and other sources.

There are no comments on this title.

to post a comment.